HIV Protease

Antiviral Agents
Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease
Thomas P. Young, Neil T. Parkin, Eric Stawiski, Tami Pilot-Matias, Roger Trinh, Dale J. Kempf, Michael Norton
Antiviral Agents
HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
Soo-Yon Rhee, Jonathan Taylor, W. Jeffrey Fessel, David Kaufman, William Towner, Paolo Troia, Peter Ruane, James Hellinger, Vivian Shirvani, Andrew Zolopa, Robert W. Shafer
Antiviral Agents
HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes
Irene Lisovsky, Susan M. Schader, Jorge-Luis Martinez-Cajas, Maureen Oliveira, Daniela Moisi, Mark A. Wainberg
Antiviral Agents
Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations
Rajin Shahriar, Soo-Yon Rhee, Tommy F. Liu, W. Jeffrey Fessel, Anthony Scarsella, William Towner, Susan P. Holmes, Andrew R. Zolopa, Robert W. Shafer
LETTERS TO THE EDITOR
Both a Protective and a Deleterious Role for the L76V Mutation
Alessandra Tartaglia, Annalisa Saracino, Laura Monno, Carmine Tinelli, Gioacchino Angarano
Antiviral Agents
Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials
Anne-Geneviève Marcelin, Philippe Flandre, Jean-Michel Molina, Christine Katlama, Patrick Yeni, Francois Raffi, Zeina Antoun, Mounir Ait-Khaled, Vincent Calvez
Antiviral Agents
Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients
Anne-Genevieve Marcelin, Bernard Masquelier, Diane Descamps, Jacques Izopet, Charlotte Charpentier, Chakib Alloui, Magali Bouvier-Alias, Anne Signori-Schmuck, Brigitte Montes, Marie-Laure Chaix, Corinne Amiel, Georges Dos Santos, Annick Ruffault, Francis Barin, Gilles Peytavin, Marc Lavignon, Philippe Flandre, Vincent Calvez
Antiviral Agents
Tipranavir (TPV) Genotypic Inhibitory Quotient Predicts Virological Response at 48 Weeks to TPV-Based Salvage Regimens
Daniel Gonzalez de Requena, Stefano Bonora, Andrea Calcagno, Antonio D'Avolio, Marco Siccardi, Silvia Fontana, Maria Grazia Milia, Mauro Sciandra, Silvia Garazzino, Antonio Di Garbo, Lorena Baietto, Laura Trentini, Giovanni Di Perri
AUTHOR'S CORRECTION
Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients
Martin S. King, Richard Rode, Isabelle Cohen-Codar, Vincent Calvez, Anne-Geneviève Marcelin, George J. Hanna, Dale J. Kempf
Antiviral Agents
Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir
Sidonie Lambert-Niclot, Philippe Flandre, Ana Canestri, Gilles Peytavin, Christine Blanc, Rachid Agher, Cathia Soulié, Marc Wirden, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin

Main menu

User menu

Search

HIV Protease

Pages